Gastric protein is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
In January 1985, the sixth generation Familia/323 was fully renewed. It was available as a hatchback (with three or five doors) or four-door saloon only for the first year; wagon and cabriolet models were added in November 1985 and March 1986 respectively. The wagon was commonly sold as a light van in Japan, but for the first time it was also available as a passenger-oriented wagon model in the Japanese domestic market. In November 1986, cumulative production of Familias (excluding vans and pickups) reached five million units; at the time, Mazda was building about 40,000 Familia/323s per month. In January 1987 a personal coupé version with its own bodywork, the Étude, was added. In February 1987 the Familia range underwent a light facelift that included replacing the old E engines with the more modern B series. In some markets, such as Indonesia, the E engine continued to be installed after the facelift. This generation of the Familia/323 was also available in a version with a turbocharged DOHC engine, with either front- or four-wheel drive, producing 140 PS (103 kW). The 4WD version (sold in either a lightweight GT or fully optioned GT-X grade) introduced in October 1985, saw some success in rally's Group A category. A limited production Japanese-only homologation special, the 4WD GT-Ae, appeared May 1988 and offered an additional ten horsepower and viscous rear limited slip differential (similar to the later BG Familia). Full time four-wheel drive was also available in more pedestrian versions like the 1.5 hatchback.
Alkylglycerone phosphate synthase (EC 2.5.1.26, alkyldihydroxyacetonephosphate synthase, alkyldihydroxyacetone phosphate synthetase, alkyl DHAP synthetase, alkyl-DHAP, dihydroxyacetone-phosphate acyltransferase, DHAP-AT) is an enzyme associated with Type 3 Rhizomelic chondrodysplasia punctata. This enzyme catalyses the following chemical reaction
==== Territorial Control Plan ==== On 19 June 2019, Bukele announced that his government would implement a seven-phase security Territorial Control Plan that sought to disrupt gang finances. The plan began that night at midnight. Phase one, known as "preparation", called for members of the country's security forces — the Armed Forces of El Salvador and the National Civil Police (PNC) — to be stationed in 12 of the country's 262 municipalities at locations where gangs were known to collect renta. The government also implemented a temporary state of emergency in El Salvador's 28 prisons, putting them on lockdown and banning visitors.
Sources: en.wikipedia.org
==== Initial outbreak ==== In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) was first identified in Wuhan, Hubei, China; it spread worldwide and was recognized as a pandemic by the World Health Organization (WHO) on March 11, 2020. The first confirmed case in Canada was in Ontario—reported on January 27, 2020. On March 17, Ford declared a state of emergency in Ontario, closing bars and restaurants (with the exception of take-out and delivery services), as well as libraries, theatres, cinemas, schools and daycares and all public gatherings of more than 50 people (later reduced to 5 people on March 28). Furthermore, the government announced on March 17 that Ontario had "some evidence of community transmission" of COVID-19. On March 23, Ford announced that all "non-essential" businesses would be ordered closed starting 11:59 p.m. On March 24. Ford also stated that schools would remain closed past the original April 6 opening date (on May 19 it was announced that schools would remain closed until the following school year in September). A list of 74 "essential" businesses was published later in the day on March 23. On March 25, Ford and Finance Minister Rod Phillips introduced a $17-billion response package that includes an influx of cash for the health sector, direct payments to parents and tax breaks for businesses.
== See also == List of cancer hospitals National Cancer Institute – U.S. health institute National Comprehensive Cancer Network – Non-profit organization in the U.S. Oncology – Branch of medicine dealing with, or specializing in, cancer
=== 2006: The first deaths are reported === Several of the deaths are notable due either to the publicity that followed or unusual circumstances of the case. One of the earliest published instances of a death attributed to cheese heroin was that of Karen Becerra, an 18-year-old high school senior found dead by her father in their West Dallas home on April 24, 2006. Police attributed her death to snorting cheese and drinking alcohol. On November 1, 2006, 17-year-old Keith Witherspoon died in nearby Mesquite; a story the following month in The Dallas Morning News profiled Witherspoon as "the first Dallas-area youth publicly known to have died of a heroin overdose since the 'cheese' concerns were raised." The death was also notable because Mesquite is located northeast of Dallas, indicating the problem had moved beyond its origins in the northwest quadrant of the city.
=== Names === Pizotifen is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while pizotyline is its USANTooltip United States Adopted Name. Brand names of pizotifen include Sandomigran, Mosegor, and Litec, among others.
Sources: en.wikipedia.org
1702: Pioneering English entomologist Eleanor Glanville captured a butterfly specimen in Lincolnshire, which was subsequently named the Glanville fritillary in her honour. Her extensive butterfly collection impressed fellow entomologist William Vernon, who called Glanville's work "the noblest collection of butterflies, all English, which has sham'd us". Her butterfly specimens became part of early collections in the Natural History Museum. 1702: German astronomer Maria Kirch became the first woman to discover a comet. c. 1702–1744: In Montreal, Canada, French botanist Catherine Jérémie collected plant specimens and studied their properties, sending the specimens and her detailed notes back to scientists in France. 1732: At the age of 20, Italian physicist Laura Bassi became the first female member of the Bologna Academy of Sciences. One month later, she publicly defended her academic theses and received a PhD. Bassi was awarded an honorary position as professor of physics at the University of Bologna. She was the first female physics professor in the world. 1738: French polymath Émilie du Châtelet became the first woman to have a paper published by the Paris Academy, following a contest on the nature of fire. 1740: French polymath Émilie du Châtelet published Institutions de Physique (Foundations of Physics) providing a metaphysical basis for Newtonian physics. 1748: Swedish agronomist Eva Ekeblad became the first female member of the Royal Swedish Academy of Sciences.
==== Myanmar (Burma) ==== In Myanmar, glass noodles are called kyazan (ကြာဆံ; lit. 'lotus thread'), more specifically pe kyazan (ပဲကြာဆံ, lit. 'bean lotus thread'), which is typically made with mung bean flour. The other form of kyazan, called hsan kyazan (ဆန်ကြာဆံ), refers to rice vermicelli. Kyazan is the primary starch used in a Burmese consommé called kya zan hinga, and is also used in Burmese salads.
Ancient seafaring people were aware of cephalopods, as evidenced by such artworks as a stone carving found in the archaeological recovery from Bronze Age Minoan Crete at Knossos (1900 – 1100 BC), which has a depiction of a fisherman carrying an octopus. The terrifyingly powerful Gorgon of Greek mythology may have been inspired by the octopus or squid, the octopus's body representing the severed head of Medusa, the beak as the protruding tongue and fangs, and its tentacles as the snakes.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.